Commentary
Video
42nd Annual CFS Preview for Medical Oncologists: The Show and After Show
Author(s):
OncLive co-hosts Kristie L. Kahl and Andrew Svonavec talk to program co-chair Benjamin P. Levy, MD, to highlight what to expect in the latest oncology developments from the 42nd Annual Chemotherapy Foundation Symposium to be held in New York City.
In its 42nd year, medical oncologists have much to look forward to at the annual Chemotherapy Foundation Symposium (CFS), with the aim of promoting delivery of evidence-based, state-of-the-art cancer care.
In the next episode of The Show and After Show, co-hosts Kristie L. Kahl and Andrew Svonavec talk to program co-chair Benjamin P. Levy, MD, associate professor, Johns Hopkins School of Medicine, and clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospital, about what to expect from attending the symposium, as well as places to visit and eat in New York City.
“This is a unique opportunity to bring in world-renowned experts in different disease states to give their insights, their perspectives, their overview on what's happening in the oncology field,” Levy said. “This range is everything from [chronic lymphocytic leukemia] all the way to prostate cancer. And this meeting has become more relevant because the science is rapidly evolving at a much quicker pace than it ever was, certainly when I started in the field.”
Levy added that the symposium will highlight education around antibody drug conjugates, diagnostics, novel targeted therapies, and more.
Additional learning objectives will:
- Compare the risks and benefits of treatment regimens based on recent clinical trials across solid and liquid tumors
- Apply strategies to identify and mitigate treatment-related adverse effects associated with solid and liquid tumor treatment approaches
- Incorporate individual patient and disease characteristics in treatment decisions to optimally manage solid and liquid tumors
- Determine optimal therapy based on biomarker testing across multiple solid and liquid tumors
CFS, to be held in New York City from November 13-15, 2024, will offer exciting new developments and rapid changes that continue to occur in the management of solid and hematologic malignancies. To learn more about CFS, or to register for the symposium, visit 42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®.
This is just a taste of the wealth of information and inspiration waiting at the 42nd Annual CFS. Check back for future meeting previews with The Show and After Show.
Registration for the 42nd Annual CFS can be found here.
